Stock comparison
Genmab A/S
Dr. Reddy's Laboratories Limited
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
RDY
Dr. Reddy's Laboratories Limited
Market cap
$11.32B
Sector
Healthcare
Overall winner
Genmab A/S GMAB
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GMAB | RDY | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 57C | GMAB |
| Benjamin Graham | 64C | 72B | RDY |
| Philip Fisher | 48D | 61C | RDY |
| Peter Lynch | 25F | 55C | RDY |
| Joel Greenblatt | 76B | 46D | GMAB |
| Charlie Munger | 68C | 49D | GMAB |
| Terry Smith | 71C | 45D | GMAB |
Side-by-side metrics
| Metric | GMAB | RDY |
|---|---|---|
| Market cap | $16.5B | $11.32B |
| P/E (TTM) | 6.2x | 26.0x |
| EV/EBIT | 12.0x | 24.0x |
| ROIC (TTM) | 43.78% | 8.07% |
| Gross margin | 93.88% | 52.77% |
| Net margin | 18.23% | 12.76% |
| Revenue CAGR 5y | -18.45% | 13.31% |
| EPS CAGR 5y | -23.48% | 17.36% |
| Debt / Equity | 0.1x | 0.2x |
| Dividend yield | 0.0% | 0.6% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GMAB leads on
- ROIC (TTM)43.78%vs 8.07%+82%
- P/E (TTM)6.2xvs 26.0x+76%
- Debt / Equity0.1xvs 0.2x+64%
- EV/EBIT12.0xvs 24.0x+50%
RDY leads on
- EPS CAGR 5y17.36%vs -23.48%+174%
- Revenue CAGR 5y13.31%vs -18.45%+172%
- Dividend yield0.6%vs 0.0%+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.